Treating intrahepatic cholangiocarcinoma with pemigatinib: two case reports of Nordic patients
Background: Cholangiocarcinoma (CCA) is a diverse group of aggressive liver tumors with up to 20% being intrahepatic CCA (iCCA). Up to 15% of patients with iCCA have fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Here we evaluated iCCA treatment with pemigatinib, a selective...
Saved in:
| Main Authors: | Vesa T. Väliaho, Iben Spanggaard |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-04-01
|
| Series: | Acta Oncologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actaoncologica/article/view/42073 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of risk factors of cholangiocarcinoma, role of diabetes mellitus and hepatitis B virus infection in the intrahepatic and extrahepatic cholangiocarcinoma: a retrospective case-based study in China
by: Hasan Md Rasadul, et al.
Published: (2025-07-01) -
Identification of glycolysis-related molecular subtypes and prognostic model in intrahepatic cholangiocarcinoma
by: Yue Wang, et al.
Published: (2025-08-01) -
Molecular and Pathological Heterogeneity of Synchronous Small and Large Duct Intrahepatic Cholangiocarcinoma—A Case Series
by: Savelina Popovska, et al.
Published: (2025-04-01) -
Case Report: FGFR2 inhibitor resistance via PIK3CA and CDKN2A/B in an intrahepatic cholangiocarcinoma patient with FGFR2-SH3GLB1 fusion
by: Nadja Ballin, et al.
Published: (2025-04-01) -
Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program
by: Philip Q. Ding, et al.
Published: (2025-07-01)